Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.00
SYK's Cash to Debt is ranked lower than
64% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SYK: 1.00 )
Ranked among companies with meaningful Cash to Debt only.
SYK' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.86 Max: 164.16
Current: 1
0.04
164.16
Equity to Asset 0.45
SYK's Equity to Asset is ranked lower than
74% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SYK: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
SYK' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.63 Max: 0.78
Current: 0.45
0.22
0.78
Interest Coverage N/A
SYK's Interest Coverage is ranked higher than
80% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 45.13 vs. SYK: N/A )
Ranked among companies with meaningful Interest Coverage only.
SYK' s Interest Coverage Range Over the Past 10 Years
Min: 24.67  Med: 9999.00 Max: 9999.99
Current: N/A
24.67
9999.99
F-Score: 7
Z-Score: 4.30
M-Score: -2.31
WACC vs ROIC
6.82%
21.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.62
SYK's Operating margin (%) is ranked higher than
90% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. SYK: 19.62 )
Ranked among companies with meaningful Operating margin (%) only.
SYK' s Operating margin (%) Range Over the Past 10 Years
Min: 12.88  Med: 20.21 Max: 23.93
Current: 19.62
12.88
23.93
Net-margin (%) 16.07
SYK's Net-margin (%) is ranked higher than
88% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. SYK: 16.07 )
Ranked among companies with meaningful Net-margin (%) only.
SYK' s Net-margin (%) Range Over the Past 10 Years
Min: 5.32  Med: 15.59 Max: 17.4
Current: 16.07
5.32
17.4
ROE (%) 18.97
SYK's ROE (%) is ranked higher than
90% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. SYK: 18.97 )
Ranked among companies with meaningful ROE (%) only.
SYK' s ROE (%) Range Over the Past 10 Years
Min: 5.84  Med: 18.28 Max: 21.28
Current: 18.97
5.84
21.28
ROA (%) 9.49
SYK's ROA (%) is ranked higher than
84% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. SYK: 9.49 )
Ranked among companies with meaningful ROA (%) only.
SYK' s ROA (%) Range Over the Past 10 Years
Min: 3.12  Med: 12.22 Max: 15.38
Current: 9.49
3.12
15.38
ROC (Joel Greenblatt) (%) 78.87
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. SYK: 78.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 43.65  Med: 67.54 Max: 108.58
Current: 78.87
43.65
108.58
Revenue Growth (3Y)(%) 4.90
SYK's Revenue Growth (3Y)(%) is ranked higher than
53% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. SYK: 4.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SYK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.9  Med: 11.10 Max: 32.2
Current: 4.9
4.9
32.2
EBITDA Growth (3Y)(%) 4.00
SYK's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. SYK: 4.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.1  Med: 14.30 Max: 40.8
Current: 4
-9.1
40.8
EPS Growth (3Y)(%) 3.70
SYK's EPS Growth (3Y)(%) is ranked higher than
52% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. SYK: 3.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: 19.20 Max: 157.1
Current: 3.7
-43
157.1
» SYK's 10-Y Financials

Financials (Next Earnings Date: 2016-07-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SYK Guru Trades in Q2 2015

Louis Moore Bacon 50,000 sh (New)
Ray Dalio 65,733 sh (+277.06%)
Robert Olstein 76,000 sh (+4.11%)
PRIMECAP Management 295,500 sh (unchged)
Eric Mindich 389,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Dodge & Cox 3,360 sh (unchged)
Ken Fisher Sold Out
Steven Cohen Sold Out
Jana Partners Sold Out
Diamond Hill Capital 985,688 sh (-0.07%)
Jeremy Grantham 2,127,956 sh (-10.53%)
Yacktman Fund 2,400,000 sh (-21.31%)
Donald Yacktman 4,883,871 sh (-23.28%)
Yacktman Focused Fund 1,600,000 sh (-30.43%)
Paul Tudor Jones 4,214 sh (-75.23%)
Jim Simons 53,300 sh (-78.29%)
Joel Greenblatt 3,101 sh (-92.27%)
» More
Q3 2015

SYK Guru Trades in Q3 2015

Steven Cohen 255,600 sh (New)
John Hussman 30,000 sh (New)
Louis Moore Bacon 120,000 sh (+140.00%)
Paul Tudor Jones 7,500 sh (+77.98%)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 295,500 sh (unchged)
Dodge & Cox 3,360 sh (unchged)
Ray Dalio Sold Out
Eric Mindich Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
Diamond Hill Capital 923,529 sh (-6.31%)
Yacktman Fund 2,000,000 sh (-16.67%)
Jeremy Grantham 1,690,876 sh (-20.54%)
Robert Olstein 49,000 sh (-35.53%)
Donald Yacktman 3,143,750 sh (-35.63%)
Yacktman Focused Fund 400,000 sh (-75.00%)
» More
Q4 2015

SYK Guru Trades in Q4 2015

Pioneer Investments 26,932 sh (New)
Jim Simons 26,100 sh (New)
Ray Dalio 12,164 sh (New)
Paul Tudor Jones 207,500 sh (+2666.67%)
Vanguard Health Care Fund 2,498,900 sh (+74.32%)
Robert Olstein 52,000 sh (+6.12%)
Diamond Hill Capital 936,985 sh (+1.46%)
PRIMECAP Management 295,500 sh (unchged)
Dodge & Cox Sold Out
John Hussman Sold Out
Louis Moore Bacon Sold Out
Yacktman Focused Fund Sold Out
Jeremy Grantham 1,467,369 sh (-13.22%)
Yacktman Fund 1,700,000 sh (-15.00%)
Donald Yacktman 2,061,165 sh (-34.44%)
Steven Cohen 18,800 sh (-92.64%)
» More
Q1 2016

SYK Guru Trades in Q1 2016

Murray Stahl 2,000 sh (New)
George Soros 20,300 sh (New)
Joel Greenblatt 85,828 sh (New)
Pioneer Investments 37,559 sh (+39.46%)
PRIMECAP Management 295,500 sh (unchged)
Vanguard Health Care Fund 2,498,900 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
Diamond Hill Capital 917,488 sh (-2.08%)
Donald Yacktman 1,948,574 sh (-5.46%)
Yacktman Fund 1,600,000 sh (-5.88%)
Jeremy Grantham 1,287,095 sh (-12.29%)
Robert Olstein 45,000 sh (-13.46%)
Paul Tudor Jones 4,200 sh (-97.98%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:ABT, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:EW, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:WILYY, OTCPK:CHEOY, NAS:ABMD, OTCPK:FSPKF, NAS:NUVA, NAS:IART, OTCPK:EKTAY, OTCPK:GGNDF » details
Traded in other countries:SYK.Germany, SYK.Switzerland, 0R2S.UK,
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Stryker Corp was incorporated in Michigan in 1946. It is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products. Its business segments are Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics products consist of implants used in hip and knee joint replacements and trauma and extremities surgeries. The Company supports surgeons with the technology and services needed as the company develops new surgical techniques. The MedSurg products include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other medical device products used in a variety of medical specialties. The Neurotechnology and Spine products include both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques; a comprehensive line of products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also develops, manufacture and market spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. The Company's competitors include Zimmer Biomet Holdings, Inc. (Zimmer), DePuy Synthes (companies of Johnson & Johnson) and Smith & Nephew plc (Smith & Nephew). The Company's businesses are subject to varying degrees of governmental regulation in the countries in which the company operates and the general trend is toward increasingly stringent regulation.

Top Ranked Articles about Stryker Corp

Answers to the Hardest Question: When Do I Sell a Stock? There are 2 primary reasons it makes sense to sell a stock
The most common complaint I have heard from investors over my 40-plus years in the financial services industry is as follows: "Everyone wants to tell me what to buy and when, but no one ever tells me when to sell." Read more...
Donald Yacktman Comments on Stryker and Anthem
During the second quarter, top contributors included Microsoft (NASDAQ:MSFT), Stryker (NYSE:SYK) and Anthem (NYSE:ANTM). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.44
SYK's P/E(ttm) is ranked lower than
52% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.63 vs. SYK: 27.44 )
Ranked among companies with meaningful P/E(ttm) only.
SYK' s P/E(ttm) Range Over the Past 10 Years
Min: 11.31  Med: 24.84 Max: 70.9
Current: 27.44
11.31
70.9
Forward P/E 20.24
SYK's Forward P/E is ranked higher than
65% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. SYK: 20.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.44
SYK's PE(NRI) is ranked lower than
52% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.92 vs. SYK: 27.44 )
Ranked among companies with meaningful PE(NRI) only.
SYK' s PE(NRI) Range Over the Past 10 Years
Min: 11.3  Med: 24.96 Max: 71.37
Current: 27.44
11.3
71.37
Price/Owner Earnings (ttm) 357.28
SYK's Price/Owner Earnings (ttm) is ranked lower than
94% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. SYK: 357.28 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SYK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.61  Med: 25.52 Max: 355.46
Current: 357.28
12.61
355.46
P/B 5.00
SYK's P/B is ranked lower than
70% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. SYK: 5.00 )
Ranked among companies with meaningful P/B only.
SYK' s P/B Range Over the Past 10 Years
Min: 2.19  Med: 3.38 Max: 7.08
Current: 5
2.19
7.08
P/S 4.42
SYK's P/S is ranked lower than
65% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. SYK: 4.42 )
Ranked among companies with meaningful P/S only.
SYK' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 3.33 Max: 5.29
Current: 4.42
1.94
5.29
PFCF 116.47
SYK's PFCF is ranked lower than
93% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.37 vs. SYK: 116.47 )
Ranked among companies with meaningful PFCF only.
SYK' s PFCF Range Over the Past 10 Years
Min: 11.77  Med: 19.85 Max: 115.89
Current: 116.47
11.77
115.89
POCF 61.68
SYK's POCF is ranked lower than
92% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. SYK: 61.68 )
Ranked among companies with meaningful POCF only.
SYK' s POCF Range Over the Past 10 Years
Min: 10.32  Med: 17.00 Max: 61.36
Current: 61.68
10.32
61.36
EV-to-EBIT 22.19
SYK's EV-to-EBIT is ranked lower than
52% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 20.28 vs. SYK: 22.19 )
Ranked among companies with meaningful EV-to-EBIT only.
SYK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 14.80 Max: 35.3
Current: 22.19
6.8
35.3
EV-to-EBITDA 18.43
SYK's EV-to-EBITDA is ranked lower than
53% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. SYK: 18.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 12.20 Max: 25.6
Current: 18.43
5.5
25.6
Shiller P/E 38.39
SYK's Shiller P/E is ranked higher than
55% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.52 vs. SYK: 38.39 )
Ranked among companies with meaningful Shiller P/E only.
SYK' s Shiller P/E Range Over the Past 10 Years
Min: 20.27  Med: 30.18 Max: 71.26
Current: 38.39
20.27
71.26
Current Ratio 3.55
SYK's Current Ratio is ranked higher than
63% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. SYK: 3.55 )
Ranked among companies with meaningful Current Ratio only.
SYK' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.67 Max: 5.37
Current: 3.55
1.61
5.37
Quick Ratio 3.00
SYK's Quick Ratio is ranked higher than
66% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. SYK: 3.00 )
Ranked among companies with meaningful Quick Ratio only.
SYK' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 2.11 Max: 4.63
Current: 3
0.98
4.63
Days Inventory 181.96
SYK's Days Inventory is ranked lower than
68% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. SYK: 181.96 )
Ranked among companies with meaningful Days Inventory only.
SYK' s Days Inventory Range Over the Past 10 Years
Min: 122.52  Med: 159.06 Max: 176.11
Current: 181.96
122.52
176.11
Days Sales Outstanding 57.71
SYK's Days Sales Outstanding is ranked higher than
67% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. SYK: 57.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
SYK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.56  Med: 61.40 Max: 62.7
Current: 57.71
58.56
62.7
Days Payable 43.33
SYK's Days Payable is ranked lower than
67% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. SYK: 43.33 )
Ranked among companies with meaningful Days Payable only.
SYK' s Days Payable Range Over the Past 10 Years
Min: 33.46  Med: 44.78 Max: 51.96
Current: 43.33
33.46
51.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.27
SYK's Dividend Yield is ranked lower than
62% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 1.72 vs. SYK: 1.27 )
Ranked among companies with meaningful Dividend Yield only.
SYK' s Dividend Yield Range Over the Past 10 Years
Min: 0.16  Med: 1.16 Max: 1.66
Current: 1.27
0.16
1.66
Dividend Payout 0.34
SYK's Dividend Payout is ranked higher than
80% of the 113 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. SYK: 0.34 )
Ranked among companies with meaningful Dividend Payout only.
SYK' s Dividend Payout Range Over the Past 10 Years
Min: 0.18  Med: 0.28 Max: 2.03
Current: 0.34
0.18
2.03
Dividend Growth (3y) 16.20
SYK's Dividend Growth (3y) is ranked higher than
65% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. SYK: 16.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SYK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 21.60 Max: 81.9
Current: 16.2
0
81.9
Forward Dividend Yield 1.31
SYK's Forward Dividend Yield is ranked lower than
61% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. SYK: 1.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.86
SYK's Yield on cost (5-Year) is ranked higher than
69% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 1.83 vs. SYK: 2.86 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SYK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.37  Med: 2.65 Max: 3.8
Current: 2.86
0.37
3.8
3-Year Average Share Buyback Ratio 0.60
SYK's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: -3.30 vs. SYK: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.10 Max: 1.9
Current: 0.6
-0.8
1.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 93.52
SYK's Price/Net Current Asset Value is ranked lower than
97% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. SYK: 93.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SYK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.45  Med: 10.38 Max: 165.96
Current: 93.52
4.45
165.96
Price/Tangible Book 15.14
SYK's Price/Tangible Book is ranked lower than
89% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. SYK: 15.14 )
Ranked among companies with meaningful Price/Tangible Book only.
SYK' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.87  Med: 6.99 Max: 665.79
Current: 15.14
2.87
665.79
Price/Projected FCF 2.19
SYK's Price/Projected FCF is ranked lower than
53% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. SYK: 2.19 )
Ranked among companies with meaningful Price/Projected FCF only.
SYK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.77 Max: 96.23
Current: 2.19
0.92
96.23
Price/Median PS Value 1.32
SYK's Price/Median PS Value is ranked lower than
69% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. SYK: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
SYK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.10 Max: 1.69
Current: 1.32
0.63
1.69
Price/Graham Number 4.28
SYK's Price/Graham Number is ranked lower than
77% of the 137 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. SYK: 4.28 )
Ranked among companies with meaningful Price/Graham Number only.
SYK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.25  Med: 3.06 Max: 37.21
Current: 4.28
1.25
37.21
Earnings Yield (Greenblatt) (%) 4.47
SYK's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SYK: 4.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.8  Med: 6.80 Max: 14.6
Current: 4.47
2.8
14.6
Forward Rate of Return (Yacktman) (%) 1.49
SYK's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 7.22 vs. SYK: 1.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SYK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.8  Med: 15.00 Max: 27.8
Current: 1.49
-3.8
27.8

More Statistics

Revenue (TTM) (Mil) $10,062
EPS (TTM) $ 4.27
Beta0.76
Short Percentage of Float2.44%
52-Week Range $86.68 - 118.65
Shares Outstanding (Mil)373.98

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 11,142 12,063 12,840
EPS ($) 5.74 6.36 7.01
EPS w/o NRI ($) 5.74 6.36 7.01
EPS Growth Rate
(3Y to 5Y Estimate)
7.35%
» More Articles for SYK

Headlines

Articles On GuruFocus.com
Becton Dickinson: 19% EPS Growth With Good Dividends Jun 26 2016 
Answers to the Hardest Question: When Do I Sell a Stock? Jun 23 2016 
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Stryker: An Expensive Growth Play Dec 26 2015 
Louis Moore Bacon's Largest 3rd Quarter Trades Dec 23 2015 
Eric Mindich Sells Stakes in Catamaran and Alphabet in 3rd Quarter Dec 02 2015 
Weekly Insider Sells Highlights: Nike, Intuitive Surgical, Travelers Companies, Stryker Oct 26 2015 
Donald Yacktman Comments on Stryker and Anthem Aug 06 2015 
Yacktman Focused Fund 2nd Quarter 2015 Commentary Aug 05 2015 
Weekly 52-Week Highs Highlight: HUM, EBAY, SYK, FRCPRD Jun 02 2015 

More From Other Websites
Accenture Selected to Help Stryker Improve Operating Efficiencies Jun 29 2016
Stryker Corp. :SYK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 Jun 28 2016
Answers to the Hardest Question: When Do I Sell a Stock? Jun 23 2016
Stryker (SYK) Hits 52-Week High on Positive FY16 View Jun 21 2016
Stryker to host conference call on July 21, 2016 Jun 16 2016
Stryker to host conference call on July 21, 2016 Jun 16 2016
Stryker, Halo to get second chance at enhanced patent damages Jun 13 2016
Rival Offer for LDR Is Unlikely, but Never Say Never Jun 09 2016
Coverage initiated on Stryker by Guggenheim Jun 09 2016
IHI’s Holdings: How Are Moving Averages Trending? Jun 07 2016
Stryker's Slowing Rally Is a Buying Opportunity Jun 06 2016
This Biomedical Stock Is A 'Screaming Buy' Jun 06 2016
Stryker to participate in Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Stryker to participate in Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Stryker to participate in UBS 2016 Global Healthcare Conference May 17 2016
Stryker to participate in UBS 2016 Global Healthcare Conference May 17 2016
Stryker to participate in Bank of America Merrill Lynch 2016 Health Care Conference May 02 2016
Stryker to participate in Bank of America Merrill Lynch 2016 Health Care Conference May 02 2016
STRYKER CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Apr 29 2016
Stryker Acquires Stanmore Implants For £35.6 million Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)